The drug developer Bristol-Myers Squibb said it would sell ConvaTec, its wound therapy and surgical care unit, for $4.1 billion to two private equity firms.
Proceeds from the sale, to Nordic Capital and Avista Capital Partners, will be used to help finance Bristol-Myers’s strategy to shift its focus to biopharmaceuticals.
1 comment:
you have this wrong. 1) ConvaTec has a Wound Therapeutics unit and an Ostomy Care unit -- There is no surgical care unit. 2) Proceeds from the sales TO Bristol-Myers Squibb not to Avista or Nordic.
Post a Comment